Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 55 min ago
Peer-reviewedCC BYPharmaceuticals (Basel, Switzerland)

Microneedle-Delivered Plant-Derived Exosome-like Nanovesicles for Dermatological Diseases: A Comprehensive Review.

  • Letong Huang1,2,3
  • Hailong Zhang1,2
  • Jiming Han1
  • Maoyuan Zeng1
  • Hongqin Sun1
  • Yi Huang2
  • Yuxiang Li3
  • Siyu Chen1
  • Mingtao Ma1
  • Tao Song1,2
  • Jidong Zhang1,2,3,4
4 affiliations
  1. 1Department of Immunology, Zunyi Medical University, Zunyi 563000, China.
  2. 2Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Zunyi 563000, China.
  3. 3Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine, Zunyi Medical University, Zunyi 563000, China.
  4. 4Guizhou Biomanufacturing Laboratory, Zunyi Medical University, Zunyi, 563000, China.
Read full textPDFDOICite

Abstract

Plant-derived extracellular vesicle-like nanovesicles (PELNs) are being investigated as plant-derived preparations with intrinsic bioactivity and potential utility as nanocarriers. Microneedles (MNs) can create transient skin microchannels and may support localized intradermal delivery of vesicle-containing formulations. The intersection of these approaches is promising, but the available evidence remains heterogeneous and includes direct PELN-MN studies, PELN studies without MNs, and related mammalian extracellular vesicle platforms. Here we provide a comprehensive review of PELN identity, isolation, characterization, cargo, and proposed dermatological activities, followed by an assessment of MN designs relevant to vesicle delivery. We searched PubMed, Web of Science, Scopus, and Embase, screened records in duplicate, and classified each included study by the directness of evidence into studies providing direct PELN-MN skin evidence, PELN evidence without MNs, mammalian extracellular vesicle MN analogue evidence, and non-dermatological or conceptual evidence. Current limitations include uncertain vesicle identity, co-isolated plant constituents, variable preparation and dosing methods, limited controls for the mechanical effects of microneedling, and incomplete clinical follow-up. Progress toward translation will require source-specific quality attributes, orthogonal potency assays, transparent comparators, and adequately controlled clinical studies.

Related

  1. Platycladus orientalis Leaf-Derived Exosome-like Nanovesicles Delivered by Hydrogel Microneedles Restore Follicular Immune Homeostasis and Promote Hair Regeneration in Androgenetic Alopecia
    Xueying Shi, Yueming Wang, Lingai Meng +7
    BiomoleculesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  2. Dermatological Diseases and Household Behavioral Spillovers: A Conceptual Framework.
    Yuval Arbel, Netanel Kerner, Oriya Kerner +1
    Healthcare (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Microneedle-based drug delivery for inflammatory and immune-mediated ocular diseases: current applications and future perspectives.
    Baoyue Mi, Feng Jin, Jingqing Mu +1
    Drug deliveryPeer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC
  4. Actions, recommendations, and public policy solutions for the management of dermatological diseases in Latin America: a systematic review
    Kelly Estrada-Orozco, Lina María Rincón-Martínez, Nathalie Ospina-Lizarazo +8
    Frontiers in Public HealthPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMCEurope PMC
  5. Brain-computer interfaces for neurodegenerative diseases: A comprehensive review of closed-loop systems from diagnosis to neural rehabilitation
    Qingyang Shan, Jiaqi Li, Yi Wang +5
    iSciencePeer-reviewedCC BY-NC 4.0NeurologyCell PressCrossref

Cite

BibTeXRIS
BibTeX
@article{huang2026microneedledelivered,
  title = {{Microneedle-Delivered Plant-Derived Exosome-like Nanovesicles for Dermatological Diseases: A Comprehensive Review.}},
  author = {Letong Huang and Hailong Zhang and Jiming Han and Maoyuan Zeng and Hongqin Sun and Yi Huang and Yuxiang Li and Siyu Chen and Mingtao Ma and Tao Song and Jidong Zhang},
  journal = {Pharmaceuticals (Basel, Switzerland)},
  year = {2026},
  month = oct,
  doi = {10.3390/ph19101579},
  url = {https://europepmc.org/article/MED/42943276},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Microneedle-Delivered Plant-Derived Exosome-like Nanovesicles for Dermatological Diseases: A Comprehensive Review.
AU  - Letong Huang
AU  - Hailong Zhang
AU  - Jiming Han
AU  - Maoyuan Zeng
AU  - Hongqin Sun
AU  - Yi Huang
AU  - Yuxiang Li
AU  - Siyu Chen
AU  - Mingtao Ma
AU  - Tao Song
AU  - Jidong Zhang
PY  - 2026
DA  - 2026/10/05
JO  - Pharmaceuticals (Basel, Switzerland)
DO  - 10.3390/ph19101579
UR  - https://europepmc.org/article/MED/42943276
AB  - Plant-derived extracellular vesicle-like nanovesicles (PELNs) are being investigated as plant-derived preparations with intrinsic bioactivity and potential utility as nanocarriers. Microneedles (MNs) can create transient skin microchannels and may support localized intradermal delivery of vesicle-containing formulations. The intersection of these approaches is promising, but the available evidence remains heterogeneous and includes direct PELN-MN studies, PELN studies without MNs, and related mammalian extracellular vesicle platforms. Here we provide a comprehensive review of PELN identity, isolation, characterization, cargo, and proposed dermatological activities, followed by an assessment of MN designs relevant to vesicle delivery. We searched PubMed, Web of Science, Scopus, and Embase, screened records in duplicate, and classified each included study by the directness of evidence into studies providing direct PELN-MN skin evidence, PELN evidence without MNs, mammalian extracellular vesicle MN analogue evidence, and non-dermatological or conceptual evidence. Current limitations include uncertain vesicle identity, co-isolated plant constituents, variable preparation and dosing methods, limited controls for the mechanical effects of microneedling, and incomplete clinical follow-up. Progress toward translation will require source-specific quality attributes, orthogonal potency assays, transparent comparators, and adequately controlled clinical studies.
SN  - 1424-8247
ER  -